Výběr jazyka

cs
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Čeština
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Co si myslíte o doplnění účtu?

* Za doplnění vašeho účtu neúčtujeme žádnou provizi

Pfizer

PFE.US $ 43.32 USD

0.09 $ (0.21%)

Potenciál růstu

Doporučení se
ověřuje

Příjem z dividend

4.07%

1d
1t
1m
6m
Celou dobu

Přidat do košíku

1 lot = 1 akcie

Částka nákupu:

Makléřská provize:

Provize za převod:

Doporučení

Strong Buy

Hodnocení výkonu

DCF

40.34

ROE

0.15

ROA

0.06

P/S

4.76

P/B

3.16

Debt / Equity

0.56

O společnosti

An American corporation Pfizer Inc. specializes in manufacturing pharmaceutical drugs, such as Diflucan, Celebrex, Viagra. The company is almost 170 years old, and its growth peak was at the end of the 20th century when new and highly efficient results of "Pfizer" developments entered the market. The beginning of the 19th century was the time of mergers and acquisitions with the largest one being with an Irish company Allergan. Up to now, the company's existence was based on several successful developments; however, in future, it aims at abandoning this strategy and start investing in biotechnologies, for which purpose it purchased Wyeth company. A special attention will be paid to biological drugs of natural origin that slow aging. According to statistics, Pfizer accounts for more than 6% of the global drug market - the company is the leader of its sector. The company capitalization amounts to $190 billion; in 2017, the net profit amounted to $13.7 billion with annual turnover facing a slight decrease. Earlier, the stocks had been falling in price for several years, probably, due to a prolonged reorganization of the company; however, since 2016, an upward trend has become visible. As far as the further destiny of the Pfizer stocks is concerned, analysts stick to moderately optimistic opinion connected with a clear viewpoint of Ian Read who became the President of the company in 2010. His whole career has been dedicated to Pfizer; he got the highest position on the back of reorganization, has completed it and returned the company back to high financial results.


Přihlaste se k odběru investičních nápadů analytiků Freedom Finance

Zprávu budeme zasílat jednou týdně, a to pouze s nejaktuálnějšími a nejdůležitějšími informacemi

Gratulujeme!

Nyní budete vždy vědět, do kterých akcií je výhodnější investovat